



Eckert & Ziegler  
*Contributing to saving lives*



# QUARTERLY REPORT I

2021

# KEY DATA


		Q1 2020	Q1 2021	Change
Sales	€ million	44.5	44.2	-1%
Return on revenue before tax	%	18	46	+156%
EBITDA	€ million	11.1	23.0	+107%
EBIT	€ million	8.3	20.6	+148%
EBT	€ million	8.1	20.4	+152%
Net income before other shareholder's interests	€ million	5.1	13.8	+170%
Profit	€ million	5.0	13.7	+174%
Earnings per share (basic)	€	0.24	0.67	+179%
Operational cash flow	€ million	4.7	-1.7	-136%
Depreciation and amortization on non-current assets	€ million	2.8	2.4	-14%
Staff as end of period	Persons	828	843	+2%

# Q1

## MILESTONES

### SEED IMPLANTATION RECEIVES REIMBURSEMENT

Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany. This was decided by the Federal Joint Committee with effect from January 8, 2021.



### PENTIXAFOR TO START DIRECTLY IN PHASE III STUDY

PENTIXAPHARM GmbH, an associate of Eckert & Ziegler, has received confirmation from the European Medicines Agency (EMA) that its lead candidate PENTIXAFOR may be tested directly in a phase III clinical study. The agency said that there are “sufficient safety data available to initiate a phase III trial” for the Gallium-68 labelled radiodiagnostic which detects CXCR4-positive solid tumors and CXCR4-positive hematological malignancies.



### CGMP FACILITY FOR RADIOPHARMACEUTICAL SERVICES IN USA

The production site in Wilmington just north of Boston, Massachusetts will be expanded with a new production facility for the contract manufacturing of radiopharmaceuticals. The new cGMP clean room suite will be operational by end of 2021.

### DIVESTING FROM TUMOUR IRRADIATION BUSINESS

Eckert & Ziegler divest its tumour radiation equipment (HDR) business. As a first step, it has sold 51% of the shares in BEBIG Medical GmbH, into which it had transferred the HDR business, to the Chinese company TCL Healthcare Equipment (TCL) in Shanghai.





### **ORDER FOR HOT CELL CONSTRUCTION FROM DUTCH RESEARCH CENTER**

The Nuclear Research and Consultancy Group (NRG) in Petten (NL), a world-leading research institute to produce radiopharmaceuticals, orders hot cells worth several million euros to be constructed by Eckert & Ziegler.



### **NEW PRODUCTION FACILITY FOR RADIOISOTOPES IN CHINA**

Eckert & Ziegler is planning to build a new production facility for radiopharmaceuticals and radioisotopes in Jintan (PR China). The start of construction is scheduled for 2021.



### **AWARD FOR EXCELLENT TRAINING QUALITY**

For the second time in a row, Eckert & Ziegler is awarded by the Berlin Chamber of Industry and Commerce (IHK) for the special quality of its training and receives the seal of approval for "Excellent Training Quality".



# A. GROUP INTERIM MANAGEMENT REPORT

## A.1 EARNINGS PERFORMANCE

In the first quarter of 2021, the Eckert & Ziegler Group achieved a new record result with a net profit of €13.7 million. Compared to the same period of the previous year, Group profit thus increased significantly by €8.7 million or 170%. The increase resulted from several components. On the one hand, the sale and associated deconsolidation of the tumor equipment business generated non-recurring income of approximately €6.8 million. On the other hand, however, the operating business also continued to perform well, with both the Medical segment and the Isotope Products segment achieving significant improvements in earnings compared with the first quarter of 2020.

### Revenue

Consolidated sales at the end of March 2021 totaled €44.2 million, only slightly below the previous year's level of €44.5 million by €0.3 million or 1%. The breakdown by segments shows a slightly different development.

The Medical segment recorded another increase in sales, which rose by €0.7 million or 3% to €21.3 million despite the deconsolidation of the tumor equipment division. The encouraging picture was mirrored at the level of the main product groups. The main growth driver continues to be the pharmaceutical radioisotope business. Sales of plant engineering, laboratory equipment and brachytherapy sources also increased. Only sales in the project business (services for companies) showed a weak start into the year.

The Isotope Products segment generated sales of €24.0 million, down €0.7 million or around 3% on the first three months of 2020. One reason for this nominal decline is the weakness of the US dollar. The segment traditionally generates the majority of its sales in USD. While these were translated at an exchange rate of USD 1.10 per euro in the first quarter of 2020, the average exchange rate in the first quarter of 2021 was approximately USD 1.20 per euro.

### Earnings (net profit for the period)

The Group's record three-month earnings of €13.7 million, or €0.67 per share, are based on earnings improvements in the two operating segments, Medical and Isotope Products, as well as a one-time effect from the sale of the tumor equipment business in the Medical segment.

The sale and deconsolidation of this division contributed approximately €6.8 million to the Medical segment's earnings of €11.7 million. Adjusted for this one-off effect, the net result for the segment amounted to €4.9 million, an increase of €1.3 million or 36% on the result for the same quarter of the previous year.

Earnings in the Isotope Products segment also increased by around €1 million compared with the first quarter of 2020 to €2.5 million. The improvement in earnings is due on the one hand to a more favorable product mix, so that despite a slight decline in sales, a gross margin at around the level of the previous year's level was achieved. On the other hand, a better financial result was achieved, which in the previous year had been negatively impacted above all by loan write-downs related to the weakness of the Brazilian real.

The Group's third segment, the holding company, closed the quarter with a loss of €0.4 million, compared to an almost balanced result in the previous year. The deterioration in earnings compared to the prior-year period is mainly due to the recognition of losses in connection with the investment in a drug development company, which had not yet been incurred in the prior-year quarter.

## A.2 FINANCIAL POSITION

### Balance sheet

Total assets as of end-March 2021 have increased slightly compared to the 2020 financial statements and now amount to € 309 million (previous year: € 292 million).

On the assets side, shares in associated companies increased by €9.7 million. This increase is mainly due to the first-time at-equity consolidation of BEBIG Medical GmbH. In connection with the sale of the HDR business within the Medical segment, the companies concerned had initially been fully deconsolidated. The remaining 49% interest held by the Group was then accounted for as investments in associates. This item was offset by repayments in relation to the investment in the Americium Consortium LLC joint venture.

Trade receivables increased by €6.5 million and inventories by €3.9 million. By contrast, assets held for sale decreased in full by € 14.0 million compared with the balance sheet as of December 31, 2020, as the corresponding sale of the HDR unit was realized in March 2021.

The changes on the liabilities side mainly relate to income tax liabilities, which increased by €3.2 million, partly due to the increase in profit for the period. Liabilities directly associated with assets held for sale decreased by €3.3 million (again in connection with the sale of the HDR division).

Equity increased by € 17.0 million to € 165.9 million as of March 31, 2021. The increase resulted mainly from the net profit for the period of € 13.7 million and from the currency differences of € 3 million recognized in equity. The equity ratio rose from 51% to 54%.

### Liquidity

Operating cash flow amounted to € -1.7 million, which is significantly lower than the figure of € 4.7 million for the same period of the previous year. This was mainly due to changes in trade receivables and the disposals of assets and liabilities held for sale in connection with the sale of the HDR business. Trade receivables increased by €6.3 million in the first three months of 2021, compared with a decrease of € 0.3 million in the same period of the previous year.

Cash flow from investing activities amounted to € 1.3 million, roughly the same amount as in the prior-year period (€ 1.5 million), which was used for the acquisition of non-current assets. In addition, € 0.1 million has been paid to date in 2021 for the investment in a joint venture (previous year: € 0.2 million). The Group received a total of € 10.4 million from the sale of shares in consolidated companies after deduction of the cash transferred on sale; in the previous year, there were no similar sales. In connection with the liquidation of the Americium Consortium LLC joint venture, the Group received repayments of € 0.8 million in the first three months of 2021.

Cash flow from financing activities, including interest payments, totaled € 0.9 million (previous year: € 0.9 million) and was used to repay loan and lease liabilities. In addition, a dividend payment of € 0.3 million was made to minority shareholders in the first quarter of the previous year.

In total, cash and cash equivalents as of March 31, 2021 increased by €8.3 million compared to the end of 2020 to €95.8 million.

## A.3 OUTLOOK

Although almost half (48%) of the 2021 annual income goal of €29 million was already achieved in the first quarter, the Executive Board for now sticks to the guidance published in March due to the ongoing pandemic, the travel restrictions that continue to hamper business, and the extended delivery times for preliminary products, for example in plant construction.

## **A.4 RISKS AND OPPORTUNITIES**

In the Annual Report 2020 we described risks that could have a significant adverse impact on our business, net assets, financial position and results of operations, as well as our reputation. The most significant opportunities and the structure of our risk management system were also described.

Additional risks and opportunities of which we are not aware or which we currently consider immaterial could also affect our business. At present, no risks have been identified that individually or in combination with other risks could potentially threaten us moving forward as a going concern.

## **A.5 ADDITIONAL INFORMATION**

### **Employees**

As of March 31, 2021, the Eckert & Ziegler Group employed 843 people worldwide. Compared to the previous year (December 31, 2020), the number of employees has thus increased slightly.

# B. INTERIM CONSOLIDATED FINANCIAL STATEMENTS

## B.1 CONSOLIDATED INCOME STATEMENT OF PROFIT OR LOSS

€ thousand	Quarterly Report I 1–3/2021	Quarterly Report I 1–3/2020
Revenues	44,160	44,479
Cost of sales	–20,306	–22,693
<b>Gross profit on sales</b>	<b>23,854</b>	<b>21,786</b>
Selling expenses	–5,922	–5,895
General and administrative expenses	–6,784	–6,502
Other operating income	10,600	287
Other operating expenses	–1,610	–897
<b>Profit from operations</b>	<b>20,138</b>	<b>8,779</b>
Results from shares measured at equity	–265	0
Other financial results	717	–493
<b>Earnings before interest and taxes (EBIT)</b>	<b>20,590</b>	<b>8,286</b>
Interest received	61	15
Interest paid	–252	–243
<b>Profit before tax</b>	<b>20,399</b>	<b>8,058</b>
Income tax expense	–6,586	–2,946
<b>Net income/loss from continuing operations</b>	<b>13,813</b>	<b>5,112</b>
Profit (–)/loss (+) attributable to minority interests	64	–89
<b>Profit attributable to the shareholders of Eckert &amp; Ziegler AG</b>	<b>13,749</b>	<b>5,023</b>
<b>Earnings per share</b>		
Basic	0.67	0.24
Diluted	0.67	0.24
Average number of shares in circulation (basic)	20,590	20,590
Average number of shares in circulation (diluted)	20,590	20,590



## B.2 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

€ thousand	Quarterly Report I 1–3/2021	Quarterly Report I 1–3/2020
<b>Profit for the period</b>	<b>13,813</b>	<b>5,112</b>
of which attributable to shareholders of Eckert & Ziegler AG	13,749	5,023
of which attributable to other shareholders	64	89
<b>Items that could subsequently be reclassified into the income statement if certain conditions are met</b>		
Adjustment of balancing item from the currency translation of foreign subsidiaries	3,318	356
Amount reposted to income statement	–301	0
<b>Currency differences from the translation of foreign operations</b>	<b>3,017</b>	<b>356</b>
<b>Items that will not be reclassified to the profit or loss statement in the future</b>		
Profit from equity instruments designated at fair value through other comprehensive income	–28	0
Deferred taxes	8	0
<b>Net profit from equity instruments designated at fair value through other comprehensive income</b>	<b>–20</b>	<b>0</b>
Change in actuarial profits (+)/losses (–) from defined benefit pension commitments	0	0
Deferred taxes	0	0
<b>Net loss from revaluation of defined benefit obligation</b>	<b>0</b>	<b>0</b>
	–20	0
<b>Other comprehensive income after taxes</b>	<b>2,997</b>	<b>356</b>
<b>Consolidated comprehensive income</b>		
of which attributable to shareholders of Eckert & Ziegler AG	16,761	5,450
of which attributable to non-controlling interests	0	0

## B.3 CONSOLIDATED BALANCE SHEET

€ thousand	March 31, 2021	Dec 31, 2020
<b>ASSETS</b>		
<b>Non current assets</b>		
Goodwill	33,177	32,448
Other intangible assets	9,808	8,974
Property, plant and equipment	38,446	38,016
Rights of use (IFRS 16)	21,832	19,845
Investments in affiliates or joint ventures	16,626	6,895
Deferred tax assets	9,268	11,898
Other non-current assets	1,088	1,085
<b>Total non-current assets</b>	<b>130,245</b>	<b>119,161</b>
<b>Current assets</b>		
Cash and cash equivalents	95,768	87,475
Securities	1,107	1,135
Trade accounts receivable	34,720	28,199
Inventories	37,491	33,574
Income tax receivables	4,053	3,027
Other current assets	5,892	5,452
Non-current assets held for sale and disposal groups	0	13,980
<b>Total current assets</b>	<b>179,031</b>	<b>172,842</b>
<b>Total assets</b>	<b>309,276</b>	<b>292,003</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholder's equity</b>		
Subscribed capital	21,172	21,172
Capital reserves	54,334	54,188
Retained earnings	97,471	83,722
Other reserves	-2,728	-5,740
Own shares	-5,519	-5,519
<b>Portion of equity attributable to the shareholders of Eckert &amp; Ziegler AG</b>	<b>164,730</b>	<b>147,823</b>
Minority interests	1,145	1,096
<b>Total shareholders' equity</b>	<b>165,875</b>	<b>148,919</b>
<b>Non-current liabilities</b>		
Long-term debt	1	2
Long-term lease obligations (IFRS 16)	19,738	17,852
Deferred income from grants and other deferred income	1,717	1,727
Deferred tax liabilities	2,823	2,210
Retirement benefit obligations	14,397	14,443
Other non-current provisions	56,281	55,743
Other non-current liabilities	1,980	1,983
<b>Total non-current liabilities</b>	<b>96,937</b>	<b>93,960</b>
<b>Current liabilities</b>		
Short-term debt	4	4
Current portion of lease obligations (IFRS 16)	2,710	2,545
Trade accounts payable	4,847	5,020
Advance payments received	4,092	8,620
Deferred income from grants and other deferred income (current)	33	38
Income tax liabilities	10,051	6,899
Other current provisions	4,141	4,062
Other current liabilities	20,586	18,672
Liabilities directly associated with assets and disposal groups held for sale assets and disposal groups	0	3,264
<b>Total current liabilities</b>	<b>46,464</b>	<b>49,124</b>
<b>Total equity and liabilities</b>	<b>309,276</b>	<b>292,003</b>

## B.4 CONSOLIDATED CASH-FLOW STATEMENT

€ thousand	Quarterly Report 1/1 – 3/31/2021	Quarterly Report 1/1 – 3/31/2020
<b>Cash flows from operating activities:</b>		
Profit for the period	13,813	5,112
Adjustments for:		
Depreciation and value impairments	2,429	2,819
Net interest income [interest expense (+)/income (-)]	191	228
Income tax expense	6,586	2,946
Income tax payments	-1,360	-547
Non-cash release of deferred income from grants	-15	-20
Gains (-)/losses on the disposal of non-current assets	0	11
Change in the non-current provisions, other non-current liabilities	-286	392
Change in other non-current assets and receivables	-1	-55
Miscellaneous	-15,041	732
Changes in current assets and liabilities:		
Receivables	-6,292	282
Inventories	-3,969	-1,914
Accruals, other current assets	160	-1,016
Change in the current liabilities and provisions	2,066	-4,224
<b>Cash inflows generated from operating activities</b>	<b>-1,719</b>	<b>4,746</b>
<b>Cash flows from investing activities:</b>		
Purchase (-)/sale of non-current assets	-1,279	-1,465
Income from the sale of shares in consolidated companies	10,380	0
Investments in or sales of affiliates	-70	-181
Income from investments	834	0
<b>Cash inflows/outflows from investment activity</b>	<b>9,865</b>	<b>-1,646</b>
<b>Cash flows from financing activities:</b>		
Distribution of shares of third parties	0	-346
Outflows for the repayment of loans and lease liabilities	-728	-698
Interest received	61	0
Interest received vs. interest paid	-215	-190
<b>Cash outflows from financing activities</b>	<b>-882</b>	<b>-1,234</b>
Effect of exchange rates on cash and cash equivalents	1,027	55
<b>Increase/reduction in cash and cash equivalents</b>	<b>8,291</b>	<b>1,921</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>87,475</b>	<b>78,922</b>
<b>Cash and cash equivalents at end of period</b>	<b>95,766</b>	<b>80,843</b>

## B.5 CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY

	Subscribed capital				Cumulative other equity items						
	Number Piece	Nominal value	Capital reserve	Retained reserves	Unrealized profit securities	Unrealized profit pension commit- ments	Foreign currency exchange differences	Own shares	Equity attributable to sharehol- ders' equity	Minority shares	Group share holders' equity
		€ thousand	€ thousand	€ thousand							
<b>As of January 1, 2020</b>	<b>5,292,983</b>	<b>5,293</b>	<b>53,763</b>	<b>85,468</b>	<b>0</b>	<b>-3,930</b>	<b>3,120</b>	<b>-5,519</b>	<b>138,195</b>	<b>1,246</b>	<b>139,441</b>
Total of expenditures and income directly entered in equity	0	0	0	0	162	-606	-4,486	0	-4,930	-31	-4,961
Net profit for the year	0	0	0	22,884	0	0	0	0	22,884	227	23,111
Total income for the period	0	0	0	22,884	162	-606	-4,486	0	17,954	196	18,150
Dividends paid/resolved	0	0	0	-8,751	0	0	0	0	-8,751	-346	-9,097
Capital increase/stock split	15,878,949	15,879	0	-15,879	0	0	0	0	0	0	0
Share-based payment	0	0	425	0	0	0	0	0	425	0	425
<b>As of December 31, 2020</b>	<b>21,171,932</b>	<b>21,172</b>	<b>54,188</b>	<b>83,722</b>	<b>162</b>	<b>-4,536</b>	<b>-1,366</b>	<b>-5,519</b>	<b>147,823</b>	<b>1,096</b>	<b>148,919</b>
<b>As of January 1, 2021</b>	<b>21,171,932</b>	<b>21,172</b>	<b>54,188</b>	<b>83,722</b>	<b>162</b>	<b>-4,536</b>	<b>-1,366</b>	<b>-5,519</b>	<b>147,823</b>	<b>1,096</b>	<b>148,919</b>
Total of expenditures and income directly recognized in equity	0	0	0	0	-20	0	3,032	0	3,012	-15	2,997
Net profit for the year	0	0	0	13,749	0	0	0	0	13,749	64	13,813
Total income for the period	0	0	0	13,749	-20	0	3,032	0	16,761	49	16,810
Dividends paid/resolved	0	0	0	0	0	0	0	0	0	0	0
Capital increase/stock split	0	0	0	0	0	0	0	0	0	0	0
Share-based payment	0	0	146	0	0	0	0	0	146	0	146
<b>As of March 31, 2021</b>	<b>21,171,932</b>	<b>21,172</b>	<b>54,334</b>	<b>97,471</b>	<b>142</b>	<b>-4,536</b>	<b>1,666</b>	<b>-5,519</b>	<b>164,730</b>	<b>1,145</b>	<b>165,875</b>

## B.6 NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

### General information

These interim consolidated financial statements as of March 31, 2021 comprise the financial statements of Eckert & Ziegler Strahlen- und Medizintechnik AG and its subsidiaries (hereinafter also referred to as “Eckert & Ziegler AG”).

### Accounting policies

The interim consolidated financial statements of Eckert & Ziegler AG as of March 31, 2021 have been prepared in accordance with the International Financial Reporting Standards (IFRS) applicable to interim financial reporting. All standards of the International Accounting Standards Board (IASB), London, applicable in the EU on the reporting date, as well as the valid interpretations of the International Financial Interpretations Committee (IFRIC) and the Standing Interpretations Committee (SIC) have been taken into account. The interim financial statements should be read in conjunction with the consolidated financial statements of Eckert & Ziegler AG as of December 31, 2020. The accounting and valuation methods explained in the notes to the 2020 consolidated financial statements have been applied unchanged.

When preparing the consolidated financial statements in accordance with IFRS, it is necessary to make estimates and assumptions that affect the amount and disclosure of recognized assets and liabilities, revenues and expenses. The actual results may differ from those estimates. Key assumptions and estimates are made for useful life, recoverable amounts of intangible assets and property, plant, and equipment, recoverability of receivables and the recognition and measurement of provisions. Due to rounding, individual figures may not add up precisely to the totals provided.

This interim report contains all the necessary information and adjustments required to give a true and fair view of the financial position, performance and cash flows of Eckert & Ziegler AG as at the date of the interim report. The results recorded during the current financial year are not necessarily indicative of future results.

### Scope of consolidated financial statements

The consolidated financial statements of Eckert & Ziegler AG include all companies in which Eckert & Ziegler AG is able to influence the financial and business policies (control concept), whether directly or indirectly.

### Acquisitions and disposals of companies

Effective January 1, 2021, the Eckert & Ziegler Group sold all its shares in GSG International GmbH, Freienbach, Switzerland and IPS International Processing Services, Halsbrücke, Germany. The two companies jointly handled an order from Switzerland for the reprocessing of components for the purpose of volume-reducing disposal of residual materials containing natural radionuclides. Both companies did not contribute significantly to Group sales and earnings in the previous year.

On March 24, 2021, Eckert & Ziegler BEBIG GmbH sold its tumor radiation equipment (HDR) business to the Chinese company TCL Healthcare Equipment (Shanghai) Co., Ltd. (TCL). In the first step, it sold 51% of the shares in BEBIG Medical GmbH, into which it had previously carved out the HDR business, to TCL.

The HDR business that was carved out generated sales of around € 11 million in the previous year. For the remaining 49% of the shares in BEBIG Medical GmbH, TCL received a call option until the beginning of 2024 and Eckert & Ziegler received a put option to TCL thereafter. The purchase price upon exercise of the purchase option is fixed in accordance with the purchase price provision of the agreement; the purchase price upon exercise of the put option may be higher depending on the development of the EBITDA of BEBIG Medical GmbH.

## Currency translation

The financial statements of companies outside the European Economic and Monetary Union are translated based on the ssfunctional currency concept. The following exchange rates were used for currency translation:

Country	Currency	Exchange rate on 3/31/2021	Exchange rate on 12/31/2020	Average exchange rate 01/01 – 3/31/2021	Average exchange rate 01/01 – 3/31/2020
USA	USD	1.1725	1.2271	1.2048	1.1027
Czech Republic	CZK	26.1430	26.2420	26.0702	25.6313
UK	GBP	0.8521	0.8990	0.8739	0.8623
Brazil	BRL	6.7409	6.3735	6.5990	4.9167
Switzerland	CHF	1.1070	1.0802	1.0913	1.0668

## Equity and treasury stock

As of March 31, 2021, Eckert & Ziegler AG held 581,956 of its own shares, representing 2.7% of the company's share capital.

## Segment information

### SEGMENT REPORT – INCOME STATEMENT

€ thousand	Isotope Products		Medical		Holding		Elimination		Total	
	Q1/2021	Q1/2020	Q1/2021	Q1/2020	Q1/2021	Q1/2020	Q1/2021	Q1/2020	Q1/2021	Q1/2020
Sales to external customers	22,804	23,911	21,273	20,565	83	3	0	0	44,160	44,479
Sales to other segments	1,158	737	2	36	2,041	1,827	-3,201	-2,600	0	0
Total segment sales	23,962	24,648	21,275	20,601	2,124	1,830	-3,201	-2,600	44,160	44,479
Result from investments valued at equity	0	0	0	0	-265	0	0	0	-265	0
Segment profit before interest and profit taxes (EBIT)	3,666	2,436	17,317	5,557	-378	293	-16	0	20,589	8,286
Interest expenses and revenues	-69	-157	-76	-23	-46	-48	0	0	-191	-228
Income tax expense	-997	-847	-5,589	-1,972	0	-128	0	0	-6,586	-2,946
Profit before minority interests	2,600	1,433	11,652	3,562	-424	118	-15	0	13,813	5,114

## SEGMENT REPORT – BALANCE SHEET

€ thousand	Isotope Products		Medical		Holding		Total	
	Q1/2021	Q1/2020	Q1/2021	Q1/2020	Q1/2021	Q1/2020	Q1/2021	Q1/2020
Segmental assets	166,551	160,448	136,927	112,846	122,291	122,447	425,769	395,741
Elimination of inter-segmental shares, equity investments and receivables							-116,493	-103,738
<b>Consolidated total assets</b>							<b>309,276</b>	<b>292,003</b>
Segmental liabilities	-91,061	-88,617	-65,218	-63,108	-7,572	-7,550	-163,851	-159,275
Elimination of intersegmental liabilities							20,450	16,191
<b>Consolidated liabilities</b>							<b>-143,401</b>	<b>-143,084</b>
Investments in associated companies	3,305	4,089	11,536	756	1,785	2,050	16,626	6,895
Investments (without acquisitions)	890	806	322	425	67	234	1,279	1,465
Depreciation and amortization incl. RoU according to IFRS 16	-1,317	-1,387	-819	-1,203	-294	-229	-2,430	-2,819
Impairments	0	0	0	0	0	0	0	0

**Material transactions with related parties**

With regard to material transactions with related parties, we refer to the disclosures in the consolidated financial statements for the year ended December 31, 2020.

## C. ADDITIONAL INFORMATION

### C.1 RESPONSIBILITY STATEMENT BY THE STATUTORY REPRESENTATIVES (BALANCE-SHEET OATH)

To the best of our knowledge, and in accordance with the applicable reporting principles for interim reporting, we hereby certify that the consolidated interim financial statements give a true and fair view of the financial position, performance and cash flows of the Group, and the group interim management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group for the remaining months of the current financial year.


Berlin, May 17, 2021



Dr Andreas Eckert  
Chairman of the Executive Board



Dr Harald Hasselmann  
Member of the Executive Board



Dr Lutz Helmke  
Member of the Executive Board

# FINANCIAL CALENDAR

May 17, 2021	Quarterly Report I/2021
May 27, 2021	Goldman Sachs Conference, UK (virtual)
June 2, 2021	Annual General Meeting (virtual)
August 12, 2021	Quarterly Report II/2021
November 9, 2021	Quarterly Report III/2021

*Subject to changes*

## IMPRINT

### PUBLISHER

Eckert & Ziegler  
Strahlen- und Medizintechnik AG

### DESIGN

Ligaturas – Reportdesign,  
Hamburg, Germany

### PHOTOS

Eckert & Ziegler Archiv  
Bernhard Ludewig  
Nils Hendrik Müller

## CONTACT

Eckert & Ziegler  
Strahlen- und Medizintechnik AG

Robert-Rössle-Straße 10  
13125 Berlin, Germany  
[www.ezag.com](http://www.ezag.com)

Karolin Riehle  
Investor Relations

Phone + 49 30 94 10 84 – 0  
Fax + 49 30 94 10 84 – 112  
[info@ezag.de](mailto:info@ezag.de)

ISIN DE0005659700  
WKN 565970

